Ken Griffin Tcr2 Therapeutics Inc. Put Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Put Options

2 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$0.83 - $1.44 $26,560 - $46,080
-32,000 Reduced 80.0%
8,000 $8,000
Q3 2022

Nov 14, 2022
SELL
$1.86 - $3.75 $8,370 - $16,875
-4,500 Reduced 10.11%
40,000 $72,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email